Skip to main content English


Helmuth Haslacher
Priv.-Doz. Mag. DDr. Helmuth Haslacher, BSc BABiobank Coordinator, Senior Consultant for Laboratory Medicine (Head of Preanalytics and Biobank, Head of Hematological Diagnostics)

Department of Laboratory Medicine
Position: Consultant

ORCID: 0000-0003-4605-2503
T +43 1 40400 53190

Further Information


Clinical Chemistry Tests; Clinical Laboratory Techniques; Total Quality Management

Research group(s)

  • MedUni Wien Biobank
    Research Area: The MedUni Wien Biobank considers itself as a link between basic and clinical research with the aim of enhancing research opportunities into emerging diagnostic, prognostic and predictive biomarkers and therapy strategies.

Research interests

Helmuth Haslacher is trained in human medicine, molecular biology and political science and holds the venia docendi for medical and chemical laboratory diagnostics. He coordinates the MedUni Vienna Biobank and works as a specialist for laboratory medicine at the Department of Laboratory Medicine, were he heads the Sections for "Preanalytics and Biobank" and "Hematological Diagnostics". Moreover, he is a member of the university's ethical committee. Within BBMRI, Haslacher leads the work package for quality management of the Austrian national node and is an expert for liquid biobanking for BBMRI-ERIC. His research interests include the influence of the extra-analytical phase in biomarker research and was recently expanded by the evaluation of SARS-CoV-2 serological testing strategies. To date, Haslacher has (co-)authored more than 140 papers.

Techniques, methods & infrastructure

Biobanking, serological tests, interface research/laboratory analysis, preanalytics, hematology

Selected publications

  1. Perkmann, T. et al., 2020. Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. Clinical Chemistry, 66(11), pp.1405,
  2. Bonelli, M. et al. (2022) ‘Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial’, Annals of the Rheumatic Diseases, 81(5), pp. 687–694. Available at:
  3. Mair, M.J. et al. (2022) ‘Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron’, Cancer Cell, 40(5), pp. 444–446. Available at:
  4. Haslacher, H. et al., 2017. The effect of storage temperature fluctuations on the stability of biochemical analytes in blood serum. Clinical Chemistry and Laboratory Medicine (CCLM), 55(7). Available at:
  5. Bartsch, R. et al. (2022) ‘Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial’, Nature Medicine, 28(9), pp. 1840–1847. Available at: